Kiadis Pharma januari 2018.

1.753 Posts, Pagina: « 1 2 3 4 5 6 ... 29 30 31 32 33 34 35 36 37 38 39 ... 84 85 86 87 88 » | Laatste
Teunis Moerman
0
Goede morgen, ben uitgespeeld eventjes met Kiadis, koers hebben we inderdaad op de 8,50 gekregen. Nu loslaten zal de koers nog wel wat verder naar beneden gaan er is nog steeds een dikke plus t.o.v. vrijdag.

Potentie is er genoeg met dit aandeel, maar maakt het daardoor ook verleidelijk om even een vuurtje op te stoken en dan blijkt dat velen lekker meegaan om die zogenaamde boot niet te missen.


Fijne dag verder

Teunis
Windkracht
1
En ter aanvulling op mijn bericht omtrent tijdsplanning van goedkeuring. Ik kan mij eerlijk gezegd niet voorstellen dat er nieuwe directieleden toetreden (2017) en een nieuwe commissaris (komende maanden) als zij ook maar enige twijfel zouden hebben over de markttoelating.

Elke keer als ik de bijzondere patronen zie in de koers bij Kiadis, dan houd ik het bovenstaande in mijn achterhoofd en dat motiveert mij gewoon rustig te blijven zitten.
Windkracht
0
Toch weer een mooi herstel naar de slotstand van gisteren. Herstel naar licht boven 9, verwacht ik vanmiddag nog.
Lex_
1
Voorzichtig naar boven met kleine particuliere aankopen en dan weer met een flinke klap omlaag om te cashen.
Windkracht
0
Interessant; De nieuwe commissaris is erg goed bekend met de nieuwe CEO van Novartis per februari 2018!!

Vasant (Vas) Narasimhan has been named as the global chief executive officer (CEO) of the Swiss pharmaceutical giant Novartis, making him the first Indian origin person to hold the post in a large pharma multinational.
Narasimhan, 41, a doctor from Harvard Medical School, is a second-generation immigrant in the US. His parents moved there from Tamil Nadu in the 1970s. He has been with Novartis since 2005. At present, he holds the post of global head of drug development and chief medical officer and will assume the new post from February. Before joining Novartis, he worked at McKinsey & Co.
Narasimhan replaces incumbent Joseph Jimenez who reshaped the pharma company through business swaps and sharpened its focus on new drug development in the wake of patent expiries of top selling drugs Diovan and Gleevec.
According to Bloomberg, Narasimhan is the youngest among new CEOs in a large pharma company.

Emma Walmsley, who took charge as global CEO of GlaxoSmithKline in April, is 48. David Ricks, who became CEO of Eli Lilly & Co in January, is 50.
“We will continue our legacy of bringing leading innovation to patients around the world. With our recent launches, our strong pipeline, broad capabilities, world-class leadership team and committed people, I am confident about our future,” Narasimhan said in a statement.
In 2016, Novartis notched sales of $48.5 billion and spent $9 billion on research and development globally. Its products are sold in 155 countries, including in India where it operates through a listed entity. Novartis also runs a development centre in Hyderabad, which supports its global clinical trials. Novartis India reported sales of Rs 656 crore in FY17.
Subhanu Saxena, who previously held leadership roles in Cipla and Novartis, believes Narasimhan would be able to rejuvenate the pipeline and show that innovation and access can go hand in hand to benefit millions of patients. “Joe (Joseph Jimenez) has left a more focused legacy for Vas, yet there is still much to do to build a leading pipeline and sharpen focus further," Saxena said.
“The appointment is extremely significant and is indicative of the growing stature of life-sciences professionals from India,” said Utkarsh Palnitkar, national head (life-science practice) of KPMG India.
Indians have made it to leadership roles in other big pharma companies, too, at the global level. Udit Batra serves on the executive board of German drugmaker Merck and is also the CEO of its life-science division. Ameet Nathwani, a British citizen of Indian origin, is executive vice-president of medical affairs at Sanofi.

www.business-standard.com/article/com...
Henk Knakworst
1
quote:

Windkracht schreef op 17 januari 2018 12:06:


Interessant; De nieuwe commissaris is erg goed bekend met de nieuwe CEO van Novartis per februari 2018!!

Vasant (Vas) Narasimhan has been named as the global chief executive officer (CEO) of the Swiss pharmaceutical giant Novartis, making him the first Indian origin person to hold the post in a large pharma multinational.
Narasimhan, 41, a doctor from Harvard Medical School, is a second-generation immigrant in the US. His parents moved there from Tamil Nadu in the 1970s. He has been with Novartis since 2005. At present, he holds the post of global head of drug development and chief medical officer and will assume the new post from February. Before joining Novartis, he worked at McKinsey & Co.
Narasimhan replaces incumbent Joseph Jimenez who reshaped the pharma company through business swaps and sharpened its focus on new drug development in the wake of patent expiries of top selling drugs Diovan and Gleevec.
According to Bloomberg, Narasimhan is the youngest among new CEOs in a large pharma company.

Emma Walmsley, who took charge as global CEO of GlaxoSmithKline in April, is 48. David Ricks, who became CEO of Eli Lilly & Co in January, is 50.
“We will continue our legacy of bringing leading innovation to patients around the world. With our recent launches, our strong pipeline, broad capabilities, world-class leadership team and committed people, I am confident about our future,” Narasimhan said in a statement.
In 2016, Novartis notched sales of $48.5 billion and spent $9 billion on research and development globally. Its products are sold in 155 countries, including in India where it operates through a listed entity. Novartis also runs a development centre in Hyderabad, which supports its global clinical trials. Novartis India reported sales of Rs 656 crore in FY17.
Subhanu Saxena, who previously held leadership roles in Cipla and Novartis, believes Narasimhan would be able to rejuvenate the pipeline and show that innovation and access can go hand in hand to benefit millions of patients. “Joe (Joseph Jimenez) has left a more focused legacy for Vas, yet there is still much to do to build a leading pipeline and sharpen focus further," Saxena said.
“The appointment is extremely significant and is indicative of the growing stature of life-sciences professionals from India,” said Utkarsh Palnitkar, national head (life-science practice) of KPMG India.
Indians have made it to leadership roles in other big pharma companies, too, at the global level. Udit Batra serves on the executive board of German drugmaker Merck and is also the CEO of its life-science division. Ameet Nathwani, a British citizen of Indian origin, is executive vice-president of medical affairs at Sanofi.

www.business-standard.com/article/com...


Goed gevonden!
Biobert
0
quote:

audioot schreef op 17 januari 2018 00:37:


Aantal forum leden neemt zeker toe gezien dit aandeel meer bekendheid heeft.
Echter de inhoudelijke kennis betreffende dit aandeel neemt zienderogen af gezien de matig tot laag inhoudelijke inbreng van menig forum lid.


Maar ik, Bio bert ,ben er weer en kom binnenkort met een inhoudelijke bijdrage
A3aan
0
quote:

Barend-B schreef op 17 januari 2018 09:24:


Goed, ik schets het volgende scenario. Kiadis doet een onderhandse aandelen uitgifte aan 8 euro aan partij X-Y-Z met een lockup periode tot eind december. Partij X ontvangt een mooi pakket aandelen en besluit na de lockup de boel omhoog te shuffelen middels broekzak-vestzak handel. Op een koers van +30% gaat de stekker uit het programma en is het uitdelen geblazen. Tot nu toe zijn alle aandelen ruim boven de emissieprijs verkocht, met uitzondering van wat stukken die particulieren op de weg omhoog eruit gevist hebben....De volgende keer meld deze partij zich weer bij Kiadis voor een emmissie, want dit is easy money om wat particulieren voor de gek te houden. Trek je eigen conclusies, maar de handel in dit aandeel is al maanden verrot.


U hebt het door. Zodra weer 8,00 euro of zelfs wat lager in zicht komt stap ik weer in. Ik ben ze maandag mooi kwijt geraakt. Lang niet op de topkoers, maar het was desondanks toch een mooie rit
Waaghals
1
Als je dat van je zelf zo kunt zeggen / brengen dan ben ik zéér benieuwd naar jou post. !!!!
Windkracht
0
Vers van de pers!

US biotech major Celgene (Nasdaq: CELG) is reportedly looking at what could be its second big acquisition for 2018, and is said to be discussions to purchase US CAR-T cell therapy company Juno Therapeutics (Nasdaq: JUNO) in order to bolster its blood cancer drugs portfolio.

The talks could produce a deal in the coming weeks, assuming they don’t fall apart, people familiar with the matter said, according to the Wall Street Journal. Terms of the possible deal couldn’t be learned. Juno had a market value of about $5.5 billion as of Tuesday afternoon.

The company had a market value of roughly $5.2 billion as of the close of regular trading on Tuesday, noted the WSJ. However, reacting to the current rumors, Juno’s shares leapt 44.74% to $45.60 after-hours.

Celgene agreed last week to acquire closely-held Impact Biomedicines for $1.1 billion upfront, gaining an experimental blood-cancer treatment. The value of that deal could climb to as much as $7 billion over time if the drug reaches certain milestones.

Juno and Celgene already have a partnership worth around $1 billion to Juno, focusing on chimeric antigen receptor technology (CAR-T) and T cell receptor (TCR) technologies, and in 2016 Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China.

Also, last December, Juno announced the formation of licensing agreements with multiple parties, including Eli Lilly, in order to advance its multiple myeloma program using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells.

On the negative side, Juno called a halt to development of its experimental CAR-T therapy known as JCAR015, after five patients in a clinical trial died from cerebral edema

www.thepharmaletter.com/article/celge...
www.cnbc.com/2018/01/16/celgene-is-in...
Windkracht
0
Bovenstaande nieuws laat duidelijk zien dat er nog vele acquisities zullen gaan plaatsvinden in de industrie! De vraag is niet of, maar wanneer......! (Kiadis)
Windkracht
0
Waaghals
0
Ja dat klopt.
Maar mij valt op dat er niemand durft door te drukken.
Er is / heerst géén aankoopdruk.
Windkracht
0
Kan het niet onderbouwen, maar verwacht straks een plotselinge stijging...van een paar procent. Orderboekje oogt te rustig en gecontroleerd, zeker in combinatie met het nieuws over de acquisitie van Celgene.
Windkracht
0
1.753 Posts, Pagina: « 1 2 3 4 5 6 ... 29 30 31 32 33 34 35 36 37 38 39 ... 84 85 86 87 88 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 25 nov 2020 17:35
Koers 5,260
Verschil 0,000 (0,00%)
Hoog 5,270
Laag 5,255
Volume 861.777
Volume gemiddeld 843.688
Volume gisteren 861.777